عنوان

Sandostatin® in the Treatment of Acromegaly :

(Number (ISBN

3642736947

(Number (ISBN

9783642736940

Number

b541558

Title Proper

Sandostatin® in the Treatment of Acromegaly :

General Material Designation

[Book]

Other Title Information

Consensus Round Table, Amsterdam 1987

First Statement of Responsibility

edited by Steven W.J. Lamberts.

Place of Publication, Distribution, etc.

Berlin, Heidelberg

Name of Publisher, Distributor, etc.

Springer Berlin Heidelberg

Date of Publication, Distribution, etc.

1988

Specific Material Designation and Extent of Item

(x, 171 pages 78 illustrations)

Text of Note

1. Clinical Aspects of Growth Hormone Hypersecretory States --;2. Correlation Between Preoperative Testing and Tumour Morphology in Acromegaly --;3. Acromegaly: Objectives of Therapy --;4. Surgical Treatment of Acromegaly --;5. External Radiation Therapy of Acromegaly --;6. Bromocriptine Treatment of Acromegaly --;7. Chemical Structure, Pharmacodynamic Profile and Pharmacokinetics of SMS 201-995 (Sandostatin®) --;8. Studies on the Acute and Chronic Effects of Sandostatin® in Acromegaly --;9. Medical Treatment of Acromegaly. Dopaminergic Agonists and Long-Acting Somatostatin --;10. Treatment of Acromegaly with the Somatostatin Analogue SMS 201-995 (Sandostatin®) --;11. Observations During a Clinical Trial of Sandostatin® in Acromegalic Patients --;12. Effects of Long-Term Administration of Sandostatin® (SMS 201-995) at Increasing Doses in 40 Acromegalic Patients. Results from the French Sandostatin Acromegaly Study Group --;13. Experience with Sandostatin® in Various Groups of Acromegalic Patients --;14. Treatment of Acromegaly with SMS 201-995 (Sandostatin®): Clinical, Biochemical and Morphologic Study --;15. Long-Term Treatment of Acromegaly by Continuous Subcutaneous Infusion of the Long-Acting Somatostatin Analog Sandostatin® (SMS 201-995, Octreotide) --;16. Sandostatin® (SMS 201-995) Treatment of Acromegaly: Acute and Chronic Effects --;17. Long-Term Efficacy of Sandostatin® (SMS 201-995, Octreotide) in 178 Acromegalic Patients. Results from the International Multicentre Acromegaly Study Group --;18a. Pulsatile Administration of SMS 201-995 (Sandostatin®) in the Treatment of Acromegaly --;18b. Treatment of Acromegaly with SMS 201-995 (Sandostatin®): A Collaborative Study in Japan --;19. Long-Term Treatment of Resistant Acromegaly with a Somatostatin Analog (SMS 201-995, Sandostatin®) --;20. High-Dose, Long-Term, Continuous Subcutaneous Infusion of SMS 201-995 (Sandostatin®) in Acromegaly --;21. Long-Term Therapy of Acromegaly with SMS 201-995 (Sandostatin®) --;22. Successful Treatment of Ophthalmoplegia in Acromegaly with the Somatostatin Analogue SMS 201-995 (Sandostatin®) --;23. Sandostatin® (SMS 201-995) in the Treatment of Acromegaly --;24. Somatostatin Octapeptide (SMS 201-995, Sandostatin®) in the Medical Treatment of Acromegaly --;25a. SMS 201-995 (Sandostatin®) Treatment of Therapy-Resistant Acromegaly --;25b. Sandostatin® (SMS 201-995) Can Exert a Direct Analgesic Effect --;25c. Relapsing Acromegaly Resistant to Both Bromocriptine and Sandostatin® Treatment --;26. Consensus Discussion and Conclusions.

Text of Note

Acromegaly is a relatively rare chronic disease. Since it also has disfiguring properties - especially of the head and face - acromegaly has serious psychological consequences which are reinforced by the awareness of factors such as excessive sweating.

Medicine.

Neurosciences.

Toxicology.

Class number

Book number

edited by Steven W.J. Lamberts.

Steven W J Lamberts

Electronic name

[Book]

Y